Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera wins FDA accelerated approval for TRUTAKNA in IgA nephropathy; Q3 full-approval data
Filed August 10, 2026 · Period ending August 10, 2026 · ~1 min read
Key Changes
-
high
FDA granted accelerated approval for TRUTAKNA in adult IgA nephropathy patients at risk for disease progression, based on 46% reduction from baseline and 42% reduction versus placebo in proteinuria at 36 weeks; U.S. commercial launch initiated.
Exhibit 99.1 view on EDGAR → -
high
Company aligned with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval; results expected Q3 2026, supplemental BLA submission expected Q4 2026, potential full approval in 2027.
Exhibit 99.1 view on EDGAR → -
high
Q2 2026 net loss $109.5M ($1.52 per share) versus $76.5M ($1.20 per share) in Q2 2025, reflecting higher operating expenses as company transitions to commercial stage; R&D expenses $60.1M, G&A expenses $52.4M.
Exhibit 99.1 view on EDGAR → -
medium
Cash, cash equivalents, and marketable securities $499.2M as of June 30, 2026, down from $714.6M at December 31, 2025; up to $425M available under debt facility subject to conditions; net cash used in operating activities $206.8M for six months ended June 30, 2026.
Exhibit 99.1 view on EDGAR → -
low
Nancy Boman, M.D., Ph.D. appointed Chief Regulatory Officer, succeeding William Turner who transitions to Strategic Advisor role in Q3 2026.
Exhibit 99.1 view on EDGAR →
Summary
Vera Therapeutics achieved a major commercial milestone with FDA accelerated approval of TRUTAKNA for adult IgA nephropathy patients at risk for disease progression. The approval, based on significant proteinuria reductions in the ORIGIN Phase 3 trial, positions TRUTAKNA as the first and only FDA-approved therapy targeting both BAFF and APRIL, the key upstream drivers of IgAN pathophysiology.
The company has initiated U.S. commercial launch. The regulatory path forward has been accelerated: Vera aligned with FDA on an earlier ORIGIN 3 final efficacy analysis expected in Q3 2026, with a supplemental BLA submission planned for Q4 2026 and potential full approval in 2027. This timeline could expedite the transition from accelerated to full approval status.
The Q2 2026 net loss of $109.5M reflects the company's transition to commercial stage, with operating expenses rising as it scales the TRUTAKNA launch. Cash position of $499.2M plus access to up to $425M in debt capacity provides runway for the commercial ramp and regulatory milestones ahead.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Vera Therapeutics announced Q2 2026 financial results and corporate updates via press release.
Added in current filing · verify on EDGAR →
On August 10, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026, and providing recent corporate updates.
The company disclosed its second quarter 2026 financial results through a press release. The 8-K body itself does not contain specific financial figures; those details are in the attached press release exhibit. This is a standard quarterly earnings disclosure.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.
Vera Therapeutics has aligned with the FDA on conducting an earlier final efficacy analysis from the ORIGIN 3 trial to support potential full approval of TRUTAKNA in adults with IgAN. The results are expected in Q3 2026, with an anticipated supplemental Biologics License Application (sBLA) submission to the FDA expected in Q4 2026. Potential full approval is expected in 2027. This accelerated timeline could expedite the path to full approval beyond the current accelerated approval status.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Announced the appointment of Nancy Boman, M.D., Ph.D. as Chief Regulatory Officer of Vera Therapeutics, succeeding William Turner, effective upon his retirement and transition to the role of Strategic Advisor in the third quarter of 2026
Vera Therapeutics appointed Nancy Boman, M.D., Ph.D. as Chief Regulatory Officer, succeeding William Turner who is retiring and transitioning to a Strategic Advisor role in Q3 2026. This leadership change occurs as the company navigates the regulatory path toward potential full approval of TRUTAKNA.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 18, 2026 · How we verify